You are here: Home » Companies » Financial X-Ray
Tata Motors scouts for pacts to fund Jaguar Land Rover capital expenditure
Mid-, small-cap funds continue to disappoint investors amid market meltdown
Business Standard

Dr Reddy's Labs looks to recover from Q1 blues with multiple growth drivers

Steady improvement in the US and India market growth keeps analysts positive

Topics
Dr Reddys Laboratories | Drugmaker | Pharma sector

Ujjval Jauhari  |  New Delhi 



Drugs, Pharma, medicine

Dr Reddy’s lower-than-expected performance for the June quarter and delay in key product launches led to weakness in the stock, which shed 3.4 per cent on Tuesday. Disappointment with June quarter performance was led by temporary disruption in active pharmaceutical ingredient (API) manufacturing and one-off inventory adjustments.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Tue, July 30 2019. 21:26 IST

RECOMMENDED FOR YOU

.